Henrik from Malta

Registered at the short selling broker Skilling, 5 minutes ago.

» Try Skilling you too
69% of retail CFD accounts lose money.
Don't show again

Verrica Pharmaceuticals, Inc. (VRCA) shares information

Verrica Pharmaceuticals, Inc.


24h Change

-8.90 %

VRCA

Live rate: Market closed

Stock data per Wednesday 8 Jul, 2020

VRCA
NASDAQ
9.66
9.62
8.80
-0.86 (-8.90%)
US Market is closed

Live Stock price in graph for Verrica Pharmaceuticals, Inc. (VRCA)

  • Latest Volume

    117,146 (-34.57 %)

  • Volume prev. day

    179,027

  • Avg. daily volume

    90,027

  • Market cap

    227,167,600

  • P/E ratio

    -7.18

  • Today high

    9.92

  • Today low

    8.76

  • 52 week high

    18.67

  • 52 week low

    6.79

  • YTD Change

    n/a

Quick links

 

Latest news about Verrica Pharmaceuticals, Inc.

Below you can find the most recent news posts about Verrica Pharmaceuticals, Inc., primarily from US and UK based news sources.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Verrica Pharmaceuticals Inc. (VRCA) on Behalf of Investors

Wednesday, 8 July 2020, 20:00:00
LOS ANGELES–(BUSINESS WIRE)—- $VRCA #classaction–Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Verrica Pharmaceuticals Inc. on Behalf of Investors
— Business Wire


Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Verrica Pharmaceuticals Inc. (VRCA) on Behalf of Investors

Wednesday, 1 July 2020, 00:00:00
LOS ANGELES–(BUSINESS WIRE)—- $VRCA #fraud–Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Verrica Pharmaceuticals Inc. on Behalf of Investors
— Business Wire


The Law Offices of Frank R. Cruz Announces Investigation on Behalf of Verrica Pharmaceuticals Inc. Investors (VRCA)

Tuesday, 30 June 2020, 22:00:00
LOS ANGELES–(BUSINESS WIRE)—- $VRCA #classaction–The Law Offices of Frank R. Cruz announces an investigation on behalf of Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (NASDAQ: VRCA) investors concerning the Company and its officers’ possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On June 29, 2020, Verrica disclosed receipt of a letter from the U.S. Food and Drug Administration (“FDA”) regarding the Company’s New Drug Application
— Business Wire


Is Verrica Pharmaceuticals Inc. (VRCA) A Good Stock To Buy?

Friday, 29 November 2019, 04:43:37
Does Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) represent a good buying opportunity at the moment? Let’s quickly check the hedge fund interest towards the company. Hedge fund firms constantly search out bright intellectuals and highly-experienced employees and throw away millions of dollars on satellite
— Yahoo Finance


The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit’s NASH Drug

Tuesday, 26 November 2019, 14:06:41
Here’s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Nov. 25.) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Amgen, Inc. (NASDAQ: AMGN ) Antares Pharma Inc (NASDAQ: ATRS ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Arvinas Inc (NASDAQ: ARVN ) (Guggenheim initiated coverage of stock with Buy rating and $50 price target) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) (announced achievement of enrollment target in a Phase 3 trial of drug to treat excessive daytime sleepiness and cataplexy in patients with narcolepsy) Axsome Therapeutics Inc (NASDAQ: AXSM ) Beigene Ltd (NASDAQ: BGNE ) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) BIO-TECHNE Corp (NASDAQ: TECH ) BioNTech SE – ADR (NASDAQ: BNTX ) Collegium Pharmaceutical Inc (NASDAQ: COLL ) Cue Biopharma Inc (NASDAQ: CUE ) DexCom, Inc. (NASDAQ: DXCM ) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Epizyme Inc (NASDAQ: EPZM ) ESSA Pharma Inc (NASDAQ: EPIX ) Flexion Therapeutics Inc (NASDAQ: FLXN ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Globus Medical Inc (NYSE: GMED ) Halozyme Therapeutics, Inc.
— Benzinga